Polypeptide applied to inhibition of intracellular lipid accumulation and synthesis method thereof
US-2024366713-A1 · Nov 7, 2024 · US
US2016279192A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016279192-A1 |
| Application number | US-201514958321-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 3, 2015 |
| Priority date | Apr 30, 2012 |
| Publication date | Sep 29, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a cobalamin acquisition protein, compositions containing the cobalamin acquisition protein, and the use of such compositions.
Opening claim text (preview).
1 .- 20 . (canceled) 21 . A pharmaceutical composition comprising a protein comprising an amino acid sequence having at least 90% identity with SEQ ID NO: 2, and a pharmaceutically acceptable excipient. 22 . The composition of claim 21 , wherein the protein binds Vitamin B 12 . 23 . The composition of claim 21 , wherein the protein binds Vitamin B 12 with an affinity less than 10 −5 M. 24 . The composition of claim 21 , wherein the composition is a liquid, solid, cream, or paste. 25 . A method of treating a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 21 . 26 . The method of claim 25 , wherein the composition is administered topically or orally to the subject. 27 . The method of claim 25 , wherein the composition is administered non-parenterally to the subject. 28 . The composition of claim 21 , wherein the protein binds Vitamin B 12 with an affinity from about 10 −5 M to about 10 −12 M. 29 . The composition of claim 21 , wherein the composition, when administered to a subject, is capable of reducing the growth and/or proliferation of a microorganism in or on the subject. 30 . The composition of claim 21 , wherein the protein comprises from about 0.1% (w/w) to about 90% (w/w) of the pharmaceutical composition. 31 . The composition of claim 30 , wherein the protein comprises from about 0.5% (w/w) to about 30% (w/w) of the pharmaceutical composition.
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title
involving vitamins {or their receptors} · CPC title
from invertebrates · CPC title
from algae · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.